Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Search results for

There are 22,050 results that match your search.22,050 results
  • Spurred on by success in several cases, campaigners in developing countries want to reform the patent system to recognize the place of traditional knowledge. If change comes, it will have a big impact on all patent applicants in the life sciences industry. James Nurton and Emma Barraclough report
  • In E-Toyo Global Stationery v Toyo Ink [2005], the first respondent was the registered proprietor of the trade mark Toyo in Class 16 and had been the registered proprietor since 1979. In 2002, the first respondent entered into a registered user agreement with the second respondent to use the Toyo mark. In 2004, a third party (not a party to this action) became a registered user and gained a licence to use the Toyo mark by way of a novation cum registered user agreement with the first respondent. The applicant alleged that as a result of the 2002 registered user agreement, an act of so-called "trafficking" had been committed.
  • The Singapore Patents Act was amended on July 1 2004. The amendments have brought about various changes to the search and examination options available to applicants using the PCT route. The options available for applications with filing dates both before and after July 1 2004 are outlined below.
  • By their nature, life science companies are among the more IP-dependent businesses in the corporate world. Any transactions, therefore, will require a more thorough due diligence than is the norm. Paul M Booth and Leslie Mooi outline 10 things you should know about such a company before deciding to invest in, or acquire, it
  • According to Regulation 1768/92/EEC supplementary protection certificates (SPCs) can be granted for novel medicines. They are intended to compensate for the reduced effective lifetime of patents covering such medicines.
  • On their face, transfer prices can have dangerous implications for potential damages claims in infringement cases. Phillip Beutel, Bryan Ray and Steven Schwartz outline what in-house counsel need to know to avoid pitfalls
  • New rules on criminal thresholds should make it easier for prosecutors to bring charges against IP infringers. But as the authorities struggle to manage a mounting workload, IP owners should consider taking the law into their own hands and launching private criminal prosecutions, explains Gordon Gao
  • The past year has seen important changes in the EU. It grew from 15 member states to 25 and, for the pharmaceutical industry, many new laws entered into force, were enacted, or were proposed. Linda Horton reviews the developments
  • Japanese businesses are increasingly turning to litigation to resolve their IP disputes. Lloyd Parker, Andrew Cobden and Yukihiro Otani spoke to Japanese managers to find out what lies behind the trend
  • On March 1 2005, the China Internet Network Information Center (CNNIC) issued an interpretation on its Domain Name Dispute Resolution Policy (the Interpretation) to clarify three definitions. The Interpretation took immediate effect.